



## FEP Medical Policy Manual

### FEP 7.01.68 Extracranial Carotid Artery Stenting

**Effective Policy Date: October 1, 2023**

**Original Policy Date: March 2012**

**Related Policies:**

2.01.54 - Endovascular Procedures for Intracranial Arterial Disease (Atherosclerosis and Aneurysms)

7.01.148 - Endovascular Therapies for Extracranial Vertebral Artery Disease

## Extracranial Carotid Artery Stenting

### Description

#### Description

Carotid artery angioplasty with stenting is a treatment for carotid stenosis that is intended to prevent a future stroke. It is an alternative to medical therapy and a less-invasive alternative to carotid endarterectomy (CEA).

#### OBJECTIVE

The objective of this evidence review is to determine whether the use of extracranial carotid artery stenting improves the net health outcome in individuals with carotid artery stenosis.

## POLICY STATEMENT

Carotid angioplasty with associated stenting and embolic protection may be considered **medically necessary** in individuals with:

- 50% to 99% stenosis (North American Symptomatic Carotid Endarterectomy Trial [NASCET] measurement); AND
- symptoms of focal cerebral ischemia (transient ischemic attack or monocular blindness) in the previous 120 days, symptom duration less than 24 hours, or nondisabling stroke; AND
- anatomic contraindication for carotid endarterectomy (eg, prior radiotherapy or neck surgery, lesions surgically inaccessible, spinal immobility, or tracheostomy).

Carotid angioplasty with associated stenting and embolic protection is considered **not medically necessary** for all other indications, including but not limited to, individuals with carotid stenosis who are suitable candidates for carotid endarterectomy and individuals with carotid artery dissection.

Carotid angioplasty without associated stenting and embolic protection is considered **not medically necessary** for all indications, including but not limited to, individuals with carotid stenosis who are suitable candidates for carotid endarterectomy and individuals with carotid artery dissection.

## POLICY GUIDELINES

The intent of the second investigational policy statement is that carotid angioplasty with embolic protection but without stenting is investigational. There may be unique situations where the original intent of surgery was to perform carotid angioplasty with stenting and embolic protection, but anatomic or other considerations prohibited placement of the stent.

## BENEFIT APPLICATION

Experimental or investigational procedures, treatments, drugs, or devices are not covered (See General Exclusion Section of brochure).

## FDA REGULATORY STATUS

A number of carotid artery stents and EPDs have been approved by the U.S. Food and Drug Administration (FDA) through the premarket approval (PMA) or the 510(k) process. Table 1 lists the original PMAs with product code NIM and Table 2 lists 510(k) approvals with product code NTE.

**Table 1. FDA Premarket Approvals for Carotid Artery Stents and Embolic Protection Devices**

Manufacturer	Device	PMA	PMA Date
Cordis Corp.	Cordis Precise Nitinol Stent System	P030047	Sept 2006
Abbott Vascular	Acculink Carotid Stent System and Rx Acculink Carotid Stent System	P040012	Aug 2004
Abbott Vascular	XACT Carotid Stent System	P040038	Sep 2005
Boston Scientific Corp.	Carotid Wallstent Monorail Endoprosthesis	P050019	Oct 2008
Boston Scientific Corp.	Endotex Nexstent Carotid Stent and Delivery System and Endotex Carotid Stent and Monorail Delivery System	P050025	Oct 2006
Medtronic Vascular	jProtege GPS and Protege Rx Carotid Stent Systems	P060001	Jan

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.

			2007
Medtronic Vascular	Exponent Self-Expanding Carotid Stent System with Over-the-Wire or Rapid-Exchange Delivery System	P070012	Oct 2007
Silk Road Medical, Inc.	Enroute Transcarotid Stent System	P140026	May 2015
	Enroute Transcarotid Stent System	P140026 S016	Apr 2022
W. L. Gore & Associates, Inc Gore Carotid Stent	Gore Carotid Stent	P180010	Nov 2018

FDA: Food and Drug Administration; PMA: Premarket approval.

**Table 2. FDA 510(k) Carotid Artery Stents and Embolic Protection Devices**

Manufacturer	Stents and Devices	510(k) Number	PMA/510(k) Date
Guidant, now Abbott Vascular	Accunet and RX Accunet Embolic protection system	K042218	Aug 2004
Guidant, now Abbott Vascular	Rx Accunet 2 Embolic Protection System	K042908	Nov 2004
Guidant, now Abbott Vascular	Rx Accunet Embolic Protection System	K052165	Aug 2005
Abbott Vascular	Emboshield embolic protection system	K052454	Sep 2005
Cordis Corp.	AngioGuard XP and RX emboli capture guidewire systems	K062531	Sep 2006
Boston Scientific	FilterWire EZ™ embolic protection system	K063313	Dec 2006
EV3 Inc	Spiderx	K052659	Feb 2007
EV3 Inc	Spidefx	K063204	Nov 2007
GORE	GORE Flow Reversal System	K083300	Feb 2009
GORE	GORE Embolic Filter	K103500	May 2011
Medtronic/Invatec	Mo.Ma Ultra Proximal Cerebral Protection Device	K092177	Oct 2009
Silk Road Medical	ENROUTE™ Transcarotid Stent System and ENROUTE Transcarotid Neuroprotection System	K143072	Feb 2015
Gardia Medical	Wirion	K143570	Jun 2015
Abbott Vascular	Rx Accunet Embolic Protection System	K153086	Nov 2015
Silk Road Medical, Inc.	Enroute Transcarotid Neuroprotection System	K153485	Mar 2016
Gardia Medical Ltd.	Wirion	K180023	Mar 2018
Contego Medical, LLC	Paladin Carotid Post-Dilation Balloon System With Integrated Embolic Protection (Paladin System)	K181128	Sep 2018

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.

Contego Medical, LLC	Vanguard Iep Peripheral Balloon Angioplasty System With Integrated Embolic Protection	K181529	Dec 2018
Abbott Vascular	Emboshield Nav6 Embolic Protection System, Barewire Filter Delivery Wires	K191173	Jul 2019
Cardiovascular Systems	Wirion	K200198	Mar 2020
Cardiovascular Systems	Wirion Embolic Protection System	K210282	Mar 2021
Cordis Corporation	Angioguard Xp Emboli Capture Guidewire, Angioguard Rx Emboli Capture Guidewire	K220654	Apr 2022
Contego Medical Inc.	Paladin Carotid Post-Dilation Balloon System With Integrated Embolic Protection	K221339	Jun 2022
Silk Road Medical	Enroute Transcarotid Neuroprotection System	K230402	Apr 2023

FDA: Food and Drug Administration; PMA: premarket approval.

Each FDA-approved carotid stent is indicated for combined use with an EPD to reduce risk of stroke in patients considered at increased risk for periprocedural complications from CEA who are symptomatic with greater than 50% stenosis, or asymptomatic with greater than 80% stenosis with the degree of stenosis assessed by ultrasound or angiogram, with computed tomography angiography also used. Patients are considered at increased risk for complications during CEA if affected by any item from a list of anatomic features and comorbid conditions included in each stent system's Information for Prescribers.

The RX Acculink Carotid Stent System is also approved for use in conventional risk patients (not considered at increased risk for complications during CEA) with symptoms and 70% or more stenosis by ultrasound or 50% or more stenosis by angiogram, and asymptomatic patients with 70% or more stenosis by ultrasound or 60% or more stenosis by angiogram.

The FDA-approved stents and EPDs differ in the deployment methods used once they reach the target lesion, with the rapid exchange devices designed for more rapid stent and filter expansion. The FDA has mandated postmarketing studies for EPDs, including longer follow-up for patients already reported to the FDA and additional registry studies, primarily to compare outcomes as a function of clinician training and facility experience. Each manufacturer's system is available in various configurations (eg, straight or tapered) and sizes (diameters and lengths) to match the vessel lumen that will receive the stent.

In 2015, the ENROUTE™ Transcarotid Neuroprotection System was cleared for marketing by the FDA through the 510(k) process. ENROUTE is a flow reversal device designed to be placed via direct carotid access. In April 2022, the ENROUTE Transcarotid Stent System received expanded approval for use in the treatment of individuals at standard risk of complications from CEA. For those with neurological symptoms, criteria include 70% or more stenosis by ultrasound or 50% or more stenosis by angiogram. For asymptomatic individuals, criteria include 70% or more stenosis by ultrasound or 60% or more stenosis by angiogram. The carotid bifurcation location must be a minimum of 5 cm above the clavicle to allow for the placement of the ENROUTE Transcarotid Neuroprotection System.

FDA product codes: NIM (stents) and NTE (EPDs).

## RATIONALE

### Summary of Evidence

For individuals who have carotid artery stenosis who receive carotid artery stenting (CAS), the evidence includes randomized controlled trials (RCTs) and systematic reviews of these trials. Relevant outcomes are overall survival, morbid events, and treatment-related mortality and morbidity. A substantial body of RCT evidence has compared outcomes of CAS with carotid endarterectomy (CEA) for symptomatic and asymptomatic patients with carotid stenosis. The evidence does not support the use of CAS in carotid artery disease for the average-risk patient because early adverse events are higher with CAS and long-term outcomes are similar between the 2 procedures. Data from RCTs and large database studies have established that the risk of death or stroke with CAS exceeds the threshold considered acceptable to indicate overall benefit from the procedure. Therefore, for patients with carotid stenosis who are suitable candidates for CEA, CAS does not improve health outcomes. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

## SUPPLEMENTAL INFORMATION

### Practice Guidelines and Position Statements

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

#### American Heart Association and American Stroke Association

The American Heart Association and the American Stroke Association (2021) issued guidance for the prevention of stroke in patients with stroke and transient ischemic attack (TIA).<sup>71</sup> They recommended that, for patients with severe extracranial carotid artery stenosis ipsilateral to a nondisabling stroke or TIA, the choice between carotid endarterectomy (CEA) and CAS in patients who are candidates for intervention should be patient specific. Specific recommendations for CAS or CEA are summarized in Table 3.

**Table 3. Guidelines for CAS/CEA in Extracranial Carotid Stenosis**

Recommendation	COR <sup>a</sup>	LOE <sup>b</sup>
In patients with a TIA or nondisabling ischemic stroke within the past 6 months and ipsilateral severe (70%-99%) carotid artery stenosis, CEA is recommended to reduce the risk of future stroke, provided that perioperative morbidity and mortality risk is estimated to be <6%.	1	A
In patients with recent TIA or ischemic stroke and ipsilateral moderate (50%-69%) carotid stenosis as documented by catheter-based imaging or noninvasive imaging, CEA is recommended to reduce the risk of future stroke, depending on patient-specific factors such as age, sex, and comorbidities, if the perioperative morbidity and mortality risk is estimated to be <6%.	1	B-R
In patients ≥70 years of age with stroke or TIA in whom carotid revascularization is being considered, it is reasonable to select CEA over CAS to reduce the periprocedural stroke rate.	2a	B-R
In patients in whom revascularization is planned within 1 week of the index stroke, it is reasonable to choose CEA over CAS to reduce the periprocedural stroke rate.	2a	B-R
In patients with symptomatic severe stenosis (≥70%) in whom anatomic or medical conditions are present that increase the risk for surgery (such as radiation-induced stenosis or restenosis after CEA) it is reasonable to choose CAS to reduce the periprocedural complication rate.	2a	C-LD
In symptomatic patients at average or low risk of complications associated with endovascular intervention, when the ICA stenosis is ≥70% by noninvasive imaging or >50% by catheter-based imaging and the anticipated rate of periprocedural stroke or death is <6%, CAS may be considered as an alternative to CEA for stroke prevention, particularly in patients with significant cardiovascular comorbidities predisposing to cardiovascular complications with endarterectomy.	2b	A

CAS: carotid artery angioplasty with stenting; CEA: carotid endarterectomy; COR: class of recommendation; ICA: internal carotid artery; LOE: level of evidence; TIA: transient ischemic attack.

<sup>a</sup> Class I: benefit >>> risk; Class IIa: benefit >> risk; Class IIb: benefit ≥ risk.

<sup>b</sup> Level A (data derived from multiple randomized controlled trials, meta-analyses of high-quality RCTs, or RCT corroborated by high-quality registry study); level B-R (data derived from ≥1 randomized controlled trial of moderate quality or meta-analysis of such trials); level C-LD (randomized or nonrandomized observational or registry studies with limitations of design or execution, meta-analyses of such studies, or physiological or mechanistic studies in human subjects).

#### Society for Vascular Surgery

The Society for Vascular Surgery published updated guidelines for management of extracranial cerebrovascular disease in 2022.<sup>72</sup> They recommended CEA over transfemoral CAS (TF-CAS) in low- and standard-risk patients with more than 50% symptomatic artery stenosis (strong evidence of high quality). The guidelines note that while present data are inadequate to make a recommendation on the role of transcrotid arterial

revascularization (TCAR) in low surgical risk patients with symptomatic carotid stenosis, TCAR is superior or preferable to TF-CAS or CEA for patients with high anatomic and/or physiologic surgical risk.

## American Stroke Association

The American Stroke Association (2011), along with 13 other medical societies, issued guidelines on the management of extracranial carotid and vertebral artery diseases, which are summarized in Table 4.<sup>73,74,75</sup>

**Table 4. Guidelines for Managing Patients With Extracranial Carotid and Vertebral Artery Disease**

Recommendation	COR <sup>a</sup>	LOE <sup>b</sup>
CAS is indicated as an alternative to CEA for symptomatic patients at average or low-risk of complications associated with endovascular intervention when the diameter of the lumen of the internal carotid artery is reduced by >70%, as documented by noninvasive imaging or >50% as documented by catheter angiography and the anticipated rate of periprocedural stroke or mortality is <6% (360)	I	B
Selection of asymptomatic patients for carotid revascularization should be guided by an assessment of comorbid conditions, life expectancy, and other individual factors and should include a thorough discussion of the risks and benefits of the procedure with an understanding of patient preferences	I	C
It is reasonable to choose CEA over CAS when revascularization is indicated in older patients, particularly when arterial pathoanatomy is unfavorable for endovascular intervention	Ila	B
It is reasonable to choose CAS over CEA when revascularization is indicated in patients with neck anatomy unfavorable for arterial surgery	Ila	B
When revascularization is indicated for patients with TIA or stroke and there are no contraindications to early revascularization, intervention within 2 week of the index event is reasonable rather than delaying surgery	Ila	B
Prophylactic CAS might be considered in highly selected patients with asymptomatic carotid stenosis (minimum 60% by angiography, 70% by validated Doppler ultrasound), but its effectiveness compared with medical therapy alone in this situation is not well established	Ilb	B
In symptomatic or asymptomatic patients at high-risk of complications for carotid revascularization by either CEA or CAS because of comorbidities, the effectiveness of revascularization versus medical therapy alone is not well established	Ilb	B
Carotid angioplasty and stenting might be considered when ischemic neurologic symptoms have not responded to anti-thrombotic therapy after acute carotid dissection	Ilb	C
Except in extraordinary circumstances, carotid revascularization by either CEA or CAS is not recommended when atherosclerosis narrows the lumen by <50%	III	A
Carotid revascularization is not recommended for patients with chronic total occlusion of the targeted carotid artery	III	C
Carotid revascularization is not recommended for patients with severe disability caused by cerebral infarction that precludes preservation of useful function	III	C

CAS: carotid artery angioplasty with stenting; CEA: carotid endarterectomy; COR: class of recommendation; LOE: level of evidence; TIA; transient ischemic attack.

<sup>a</sup> Class I: benefit >>> risk; class Ila benefit >> risk; class Ilb benefit ≥ risk; class III: no benefit.

<sup>b</sup> Level A (data derived from multiple randomized controlled trials or meta-analyses; multiple populations evaluated); level B (data derived from a single randomized controlled trial or nonrandomized studies; limited populations evaluated); level C (only consensus opinion of experts, case studies, or standard of care; very limited populations evaluated).

## U.S. Preventive Services Task Force Recommendations

The U.S. Preventive Services Task Force recommends against screening for asymptomatic carotid artery stenosis in the general adult population (Grade D; reaffirmed in 2021).<sup>76</sup>

## Medicare National Coverage

The Center for Medicaid & Medicare Services (CMS; 2001) issued national coverage policy that restricted coverage for carotid angioplasty and stenting to patients participating in a clinical trial with category B investigational device exemption (IDE) designation from the U.S. Food and Drug Administration (FDA). Percutaneous transluminal angioplasty of the vertebral and cerebral arteries remained noncovered.

When the FDA approved the first (Guidant) devices, Medicare coverage under the IDE was no longer available for that manufacturer's devices and was not applicable to the FDA-required postapproval studies. Thus, in 2004, Medicare broadened its national coverage policy and "determined that the evidence is adequate to conclude that percutaneous transluminal angioplasty with carotid stent placement is reasonable and necessary when performed consistent with the FDA approval of the carotid stent device and in an FDA required post-approval study." For unapproved stents and embolic protection devices, the prior policy remained in effect and restricted coverage to patients participating in an FDA-approved category B IDE trial of stent placement in the cervical carotid artery.

While the Medicare decision differed from the conclusions of this evidence review, Medicare made a public policy decision "that making available new, effective therapies aimed at addressing treatment and prevention of cerebrovascular disease was important to Medicare beneficiaries." Medicare also noted that it recognized the value in supporting postapproval studies as "the collected data may provide an opportunity for practitioners to determine which patients are most appropriate for carotid artery stenting and to reinforce IDE trial data on health outcomes and adverse events."

CMS provides a continually updated listing of facilities eligible for Medicare reimbursement that meet CMS's minimum facility standards for performing CAS for high-risk patients.

In 2005, CMS determined that CAS with embolic protection devices was reasonable and necessary for patients at high risk for CEA who also have symptomatic carotid artery stenosis 70% or more.<sup>77</sup> The CMS limited coverage for these patients to procedures performed using the FDA-approved devices. The CMS also limited coverage for patients at high risk for CEA with symptomatic carotid artery stenosis between 50% and 70%, and for patients at high risk for CEA with asymptomatic stenosis 80% or more, to the FDA-approved category B, IDE clinical trials for unapproved devices, or to the FDA-required postapproval studies for approved devices. The CMS defined patients at high-risk for CEA as having significant comorbidities and/or anatomic risk factors (ie, recurrent stenosis and/or previous radical neck dissection) who would be poor candidates for CEA in the opinion of a surgeon.

In 2007, a decision memo reaffirmed CMS's previous decision following a request to expand coverage while clarifying that "CAS is only covered when used with an embolic protection device and is, therefore, not covered if deployment of the distal embolic protection device is not technically possible." In 2008, in a sixth reconsideration, and in 2009, in a seventh reconsideration, CMS reaffirmed its prior coverage decisions.

In 2012, CMS convened a Medicare Evidence Development & Coverage Advisory Committee panel to consider management of carotid atherosclerosis. Medicare Evidence Development & Coverage Advisory Committee panel members voted on specific questions using a scale of 1 (low confidence) to 5 (high confidence). For symptomatic patients not considered at high risk, the mean scores to the question of whether CAS is the favored treatment strategy in this population was 1.85, and for CEA 3.6. For asymptomatic patients not considered high-risk, the evidence was judged to have not reached a level of certainty to determine a favored treatment.

## REFERENCES

1. Barnett HJM, Taylor DW, Haynes RB, et al. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. *N Engl J Med.* Aug 15 1991; 325(7): 445-53. PMID 1852179
2. MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe (70-99%) or with mild (0-29%) carotid stenosis. European Carotid Surgery Trialists' Collaborative Group. *Lancet.* May 25 1991; 337(8752): 1235-43. PMID 1674060
3. Mayberg MR, Wilson SE, Yatsu F, et al. Carotid endarterectomy and prevention of cerebral ischemia in symptomatic carotid stenosis. Veterans Affairs Cooperative Studies Program 309 Trialist Group. *JAMA.* Dec 18 1991; 266(23): 3289-94. PMID 1960828
4. Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. *JAMA.* May 10 1995; 273(18): 1421-8. PMID 7723155
5. Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). *Lancet.* May 09 1998; 351(9113): 1379-87. PMID 9593407
6. Barnett HJ, Taylor DW, Eliasziw M, et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. *N Engl J Med.* Nov 12 1998; 339(20): 1415-25. PMID 9811916
7. Halliday A, Mansfield A, Marro J, et al. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial. *Lancet.* May 08 2004; 363(9420): 1491-502. PMID 15135594

8. Arazi HC, Capparelli FJ, Linetzky B, et al. Carotid endarterectomy in asymptomatic carotid stenosis: a decision analysis. *Clin Neurol Neurosurg.* May 2008; 110(5): 472-9. PMID 18374476
9. Marquardt L, Geraghty OC, Mehta Z, et al. Low risk of ipsilateral stroke in patients with asymptomatic carotid stenosis on best medical treatment: a prospective, population-based study. *Stroke.* Jan 2010; 41(1): e11-7. PMID 19926843
10. Naylor AR, Bell PR. Treatment of asymptomatic carotid disease with stenting: con. *Semin Vasc Surg.* Jun 2008; 21(2): 100-7. PMID 18565417
11. Brott TG, Hobson RW, Howard G, et al. Stenting versus endarterectomy for treatment of carotid-artery stenosis. *N Engl J Med.* Jul 01 2010; 363(1): 11-23. PMID 20505173
12. De Rango P, Brown MM, Leys D, et al. Management of carotid stenosis in women: consensus document. *Neurology.* Jun 11 2013; 80(24): 2258-68. PMID 23751919
13. Jordan WD, Voellinger DC, Fisher WS, et al. A comparison of carotid angioplasty with stenting versus endarterectomy with regional anesthesia. *J Vasc Surg.* Sep 1998; 28(3): 397-402; discussion 402-3. PMID 9737448
14. Lewis SC, Warlow CP, Bodenham AR, et al. General anaesthesia versus local anaesthesia for carotid surgery (GALA): a multicentre, randomised controlled trial. *Lancet.* Dec 20 2008; 372(9656): 2132-42. PMID 19041130
15. Yadav JS, Wholey MH, Kuntz RE, et al. Protected carotid-artery stenting versus endarterectomy in high-risk patients. *N Engl J Med.* Oct 07 2004; 351(15): 1493-501. PMID 15470212
16. Gurm HS, Yadav JS, Fayad P, et al. Long-term results of carotid stenting versus endarterectomy in high-risk patients. *N Engl J Med.* Apr 10 2008; 358(15): 1572-9. PMID 18403765
17. Eckstein HH, Ringleb P, Allenberg JR, et al. Results of the Stent-Protected Angioplasty versus Carotid Endarterectomy (SPACE) study to treat symptomatic stenoses at 2 years: a multinational, prospective, randomised trial. *Lancet Neurol.* Oct 2008; 7(10): 893-902. PMID 18774746
18. Ringleb PA, Allenberg J, Brckmann H, et al. 30 day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients: a randomised non-inferiority trial. *Lancet.* Oct 07 2006; 368(9543): 1239-47. PMID 17027729
19. Naylor AR. SPACE: not the final frontier. *Lancet.* Oct 07 2006; 368(9543): 1215-6. PMID 17027708
20. Furlan AJ. Carotid-artery stenting--case open or closed?. *N Engl J Med.* Oct 19 2006; 355(16): 1726-9. PMID 17050898
21. Mas JL, Chatellier G, Beyssen B, et al. Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. *N Engl J Med.* Oct 19 2006; 355(16): 1660-71. PMID 17050890
22. Arquizan C, Trinquart L, Touboul PJ, et al. Restenosis is more frequent after carotid stenting than after endarterectomy: the EVA-3S study. *Stroke.* Apr 2011; 42(4): 1015-20. PMID 21311065
23. Mas JL, Trinquart L, Leys D, et al. Endarterectomy Versus Angioplasty in Patients with Symptomatic Severe Carotid Stenosis (EVA-3S) trial: results up to 4 years from a randomised, multicentre trial. *Lancet Neurol.* Oct 2008; 7(10): 885-92. PMID 18774745
24. Mas JL, Arquizan C, Calvet D, et al. Long-term follow-up study of endarterectomy versus angioplasty in patients with symptomatic severe carotid stenosis trial. *Stroke.* Sep 2014; 45(9): 2750-6. PMID 25082808
25. Ederle J, Dobson J, Featherstone RL, et al. Carotid artery stenting compared with endarterectomy in patients with symptomatic carotid stenosis (International Carotid Stenting Study): an interim analysis of a randomised controlled trial. *Lancet.* Mar 20 2010; 375(9719): 985-97. PMID 20189239
26. Bonati LH, Jongen LM, Haller S, et al. New ischaemic brain lesions on MRI after stenting or endarterectomy for symptomatic carotid stenosis: a substudy of the International Carotid Stenting Study (ICSS). *Lancet Neurol.* Apr 2010; 9(4): 353-62. PMID 20189458
27. Rothwell PM. Carotid stenting: more risky than endarterectomy and often no better than medical treatment alone. *Lancet.* Mar 20 2010; 375(9719): 957-9. PMID 20304225
28. Bonati LH, Dobson J, Featherstone RL, et al. Long-term outcomes after stenting versus endarterectomy for treatment of symptomatic carotid stenosis: the International Carotid Stenting Study (ICSS) randomised trial. *Lancet.* Feb 07 2015; 385(9967): 529-38. PMID 25453443
29. Altinbas A, Algra A, Brown MM, et al. Effects of carotid endarterectomy or stenting on hemodynamic complications in the International Carotid Stenting Study: a randomized comparison. *Int J Stroke.* Apr 2014; 9(3): 284-90. PMID 23834300
30. Featherstone RL, Dobson J, Ederle J, et al. Carotid artery stenting compared with endarterectomy in patients with symptomatic carotid stenosis (International Carotid Stenting Study): a randomised controlled trial with cost-effectiveness analysis. *Health Technol Assess.* Mar 2016; 20(20): 1-94. PMID 26979174
31. Hopkins LN, Roubin GS, Chakhtoura EY, et al. The Carotid Revascularization Endarterectomy versus Stenting Trial: credentialing of interventionalists and final results of lead-in phase. *J Stroke Cerebrovasc Dis.* Mar 2010; 19(2): 153-62. PMID 20189092
32. Silver FL, Mackey A, Clark WM, et al. Safety of stenting and endarterectomy by symptomatic status in the Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST). *Stroke.* Mar 2011; 42(3): 675-80. PMID 21307169
33. Lal BK, Beach KW, Roubin GS, et al. Restenosis after carotid artery stenting and endarterectomy: a secondary analysis of CREST, a randomised controlled trial. *Lancet Neurol.* Sep 2012; 11(9): 755-63. PMID 22857850
34. Brott TG, Howard G, Roubin GS, et al. Long-Term Results of Stenting versus Endarterectomy for Carotid-Artery Stenosis. *N Engl J Med.* Mar 17 2016; 374(11): 1021-31. PMID 26890472
35. Roffi M, Sievert H, Gray WA, et al. Carotid artery stenting versus surgery: adequate comparisons?. *Lancet Neurol.* Apr 2010; 9(4): 339-41; author reply 341-2. PMID 20189459
36. Nallamothu BK, Gurm HS, Ting HH, et al. Operator experience and carotid stenting outcomes in Medicare beneficiaries. *JAMA.* Sep 28 2011; 306(12): 1338-43. PMID 21954477
37. Gonzales NR, Demaerschalk BM, Voeks JH, et al. Complication rates and center enrollment volume in the carotid revascularization endarterectomy versus stenting trial. *Stroke.* Nov 2014; 45(11): 3320-4. PMID 25256180
38. Meschia JF, Brott TG, Voeks J, et al. Stroke Symptoms as a Surrogate in Stroke Primary Prevention Trials: The CREST Experience. *Neurology.* Nov 22 2022; 99(21): e2378-e2384. PMID 36028326



39. Rosenfield K, Matsumura JS, Chaturvedi S, et al. Randomized Trial of Stent versus Surgery for Asymptomatic Carotid Stenosis. *N Engl J Med*. Mar 17 2016; 374(11): 1011-20. PMID 26886419
40. Spence JD, Naylor AR. Endarterectomy, Stenting, or Neither for Asymptomatic Carotid-Artery Stenosis. *N Engl J Med*. Mar 17 2016; 374(11): 1087-8. PMID 26890473
41. Halliday A, Bulbulia R, Bonati LH, et al. Second asymptomatic carotid surgery trial (ACST-2): a randomised comparison of carotid artery stenting versus carotid endarterectomy. *Lancet*. Sep 18 2021; 398(10305): 1065-1073. PMID 34469763
42. Li FM, Zhong JX, Jiang X, et al. Therapeutic effect of carotid artery stenting versus endarterectomy for patients with high-risk carotid stenosis. *Int J Clin Exp Med*. 2014; 7(9): 2895-900. PMID 25356155
43. Kuliha M, Roubec M, Prochzka V, et al. Randomized clinical trial comparing neurological outcomes after carotid endarterectomy or stenting. *Br J Surg*. Feb 2015; 102(3): 194-201. PMID 25511816
44. Reiff T, Eckstein HH, Mansmann U, et al. Angioplasty in asymptomatic carotid artery stenosis vs. endarterectomy compared to best medical treatment: One-year interim results of SPACE-2. *Int J Stroke*. Mar 15 2019; 15(6): 1747493019833017. PMID 30873912
45. Reiff T, Eckstein HH, Mansmann U, et al. Carotid endarterectomy or stenting or best medical treatment alone for moderate-to-severe asymptomatic carotid artery stenosis: 5-year results of a multicentre, randomised controlled trial. *Lancet Neurol*. Oct 2022; 21(10): 877-888. PMID 36115360
46. Howard VJ, Meschia JF, Lal BK, et al. Carotid revascularization and medical management for asymptomatic carotid stenosis: Protocol of the CREST-2 clinical trials. *Int J Stroke*. Oct 2017; 12(7): 770-778. PMID 28462683
47. Gray WA. Carotid stenting or carotid surgery in average surgical-risk patients: interpreting the conflicting clinical trial data. *Prog Cardiovasc Dis*. 2011; 54(1): 14-21. PMID 21722782
48. Woo K, Garg J, Hye RJ, et al. Contemporary results of carotid endarterectomy for asymptomatic carotid stenosis. *Stroke*. May 2010; 41(5): 975-9. PMID 20339122
49. Barnett HJ, Pelz DM, Lownie SP. Reflections by contrarians on the post-CREST evaluation of carotid stenting for stroke prevention. *Int J Stroke*. Dec 2010; 5(6): 455-6. PMID 21050401
50. Miller MD, Lyrrer P, Brown MM, et al. Carotid artery stenting versus endarterectomy for treatment of carotid artery stenosis. *Cochrane Database Syst Rev*. Feb 25 2020; 2(2): CD000515. PMID 32096559
51. Angioplasty and stenting of the cervical carotid artery with distal embolic protection of the cerebral circulation. *Technol Eval Cent Assess Program Exec Summ*. Feb 2005; 19(15): 1-4. PMID 15714698
52. Ederle J, Featherstone RL, Brown MM. Randomized controlled trials comparing endarterectomy and endovascular treatment for carotid artery stenosis: a Cochrane systematic review. *Stroke*. Apr 2009; 40(4): 1373-80. PMID 19228850
53. Bangalore S, Kumar S, Wetterslev J, et al. Carotid artery stenting vs carotid endarterectomy: meta-analysis and diversity-adjusted trial sequential analysis of randomized trials. *Arch Neurol*. Feb 2011; 68(2): 172-184. PMID
54. Murad MH, Shahrour A, Shah ND, et al. A systematic review and meta-analysis of randomized trials of carotid endarterectomy vs stenting. *J Vasc Surg*. Mar 2011; 53(3): 792-7. PMID 21216556
55. Economopoulos KP, Sergentanis TN, Tsiygoulis G, et al. Carotid artery stenting versus carotid endarterectomy: a comprehensive meta-analysis of short-term and long-term outcomes. *Stroke*. Mar 2011; 42(3): 687-92. PMID 21233476
56. Vincent S, Eberg M, Eisenberg MJ, et al. Meta-Analysis of Randomized Controlled Trials Comparing the Long-Term Outcomes of Carotid Artery Stenting Versus Endarterectomy. *Circ Cardiovasc Qual Outcomes*. Oct 2015; 8(6 Suppl 3): S99-108. PMID 26515216
57. Brott TG, Calvet D, Howard G, et al. Long-term outcomes of stenting and endarterectomy for symptomatic carotid stenosis: a preplanned pooled analysis of individual patient data. *Lancet Neurol*. Apr 2019; 18(4): 348-356. PMID 30738706
58. Paraskevas KI, Lazaridis C, Andrews CM, et al. Comparison of cognitive function after carotid artery stenting versus carotid endarterectomy. *Eur J Vasc Endovasc Surg*. Mar 2014; 47(3): 221-31. PMID 24393665
59. Wang J, Bai X, Wang T, et al. Carotid Stenting Versus Endarterectomy for Asymptomatic Carotid Artery Stenosis: A Systematic Review and Meta-Analysis. *Stroke*. Oct 2022; 53(10): 3047-3054. PMID 35730457
60. Angioplasty and stenting of the cervical carotid artery with embolic protection of the cerebral circulation. *Technol Eval Cent Assess Program Exec Summ*. Aug 2010; 24(12): 1-3. PMID 21114063
61. Touz E, Trinquart L, Chatellier G, et al. Systematic review of the perioperative risks of stroke or death after carotid angioplasty and stenting. *Stroke*. Dec 2009; 40(12): e683-93. PMID 19892997
62. Gray WA, Chaturvedi S, Verta P. Thirty-day outcomes for carotid artery stenting in 6320 patients from 2 prospective, multicenter, high-surgical-risk registries. *Circ Cardiovasc Interv*. Jun 2009; 2(3): 159-66. PMID 20031712
63. White CJ, Iyer SS, Hopkins LN, et al. Carotid stenting with distal protection in high surgical risk patients: the BEACH trial 30 day results. *Catheter Cardiovasc Interv*. Apr 2006; 67(4): 503-12. PMID 16548004
64. Spangler EL, Goodney PP, Schanzer A, et al. Outcomes of carotid endarterectomy versus stenting in comparable medical risk patients. *J Vasc Surg*. Nov 2014; 60(5): 1227-1231.e1. PMID 24953899
65. Salzler GG, Farber A, Rybin DV, et al. The association of Carotid Revascularization Endarterectomy versus Stent Trial (CREST) and Centers for Medicare and Medicaid Services Carotid Guideline Publication on utilization and outcomes of carotid stenting among "high-risk" patients. *J Vasc Surg*. Jul 2017; 66(1): 104-111.e1. PMID 28502543
66. Naazie IN, Cui CL, Osaghae I, et al. A Systematic Review and Meta-Analysis of Transcarotid Artery Revascularization with Dynamic Flow Reversal Versus Transfemoral Carotid Artery Stenting and Carotid Endarterectomy. *Ann Vasc Surg*. Nov 2020; 69: 426-436. PMID 32505684
67. Lee VH, Brown RD, Mandrekar JN, et al. Incidence and outcome of cervical artery dissection: a population-based study. *Neurology*. Nov 28 2006; 67(10): 1809-12. PMID 17130413
68. Schirmer CM, Atalay B, Malek AM. Endovascular recanalization of symptomatic flow-limiting cervical carotid dissection in an isolated hemisphere. *Neurosurg Focus*. Jun 2011; 30(6): E16. PMID 21631217

69. Ohta H, Natarajan SK, Hauck EF, et al. Endovascular stent therapy for extracranial and intracranial carotid artery dissection: single-center experience. *J Neurosurg.* Jul 2011; 115(1): 91-100. PMID 21417710
70. Asif KS, Lazzaro MA, Teleb MS, et al. Endovascular reconstruction for progressively worsening carotid artery dissection. *J Neurointerv Surg.* Jan 2015; 7(1): 32-9. PMID 24391159
71. Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. *Stroke.* Jul 2021; 52(7): e364-e467. PMID 34024117
72. AbuRahma AF, Avgerinos ED, Chang RW, et al. Society for Vascular Surgery clinical practice guidelines for management of extracranial cerebrovascular disease. *J Vasc Surg.* Jan 2022; 75(1S): 4S-22S. PMID 34153348
73. Brott TG, Halperin JL, Abbara S, et al. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American Stroke Association, American Association of Neuroscience Nurses, American Association of Neurological Surgeons, American College of Radiology, American Society of Neuroradiology, Congress of Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of NeuroInterventional Surgery, Society for Vascular Medicine, and Society for Vascular Surgery. *J Am Coll Cardiol.* Feb 22 2011; 57(8): e16-94. PMID 21288679
74. Brott TG, Halperin JL, Abbara S, et al. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American Stroke Association, American Association of Neuroscience Nurses, American Association of Neurological Surgeons, American College of Radiology, American Society of Neuroradiology, Congress of Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of NeuroInterventional Surgery, Society for Vascular Medicine, and Society for Vascular Surgery. *Circulation.* Jul 26 2011; 124(4): e54-130. PMID 21282504
75. Brott TG, Halperin JL, Abbara S, et al. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: executive summary. *Stroke.* Aug 2011; 42(8): e420-63. PMID 21282494
76. Krist AH, Davidson KW, Mangione CM, et al. Screening for Asymptomatic Carotid Artery Stenosis: US Preventive Services Task Force Recommendation Statement. *JAMA.* Feb 02 2021; 325(5): 476-481. PMID 33528542
77. Centers for Medicare & Medicaid Services (CMS). Decision Memo for Carotid Artery Stenting (CAG-00085R). 2005; <https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=157>. Accessed April 3, 2023.

## POLICY HISTORY - THIS POLICY WAS APPROVED BY THE FEP® PHARMACY AND MEDICAL POLICY COMMITTEE ACCORDING TO THE HISTORY BELOW:

Date	Action	Description
March 2012	New policy	
June 2013	Replace policy	Policy updated with literature review; References added, renumbered, and some removed. Carotid dissection added to policy as investigational, clarified policy statement to read that CAS is investigational for those who are suitable candidates for CEA.
June 2014	Replace policy	Policy update with literature review, adding reference 12. Added transcervical approach to background. Policy statements unchanged.
June 2015	Replace policy	Policy updated with literature review adding references 24, 28-29, 35-37, 49-50 and 53. Policy statement is unchanged.
September 2016	Replace policy	Policy updated with literature review; references 30, 34, 38-39, and 54 added. Policy statements unchanged.
September 2018	Replace policy	Policy updated with literature review through March 5, 2018; references 52, 60, 69, 73, and 75 added. Investigational policy statements separated for carotid angioplasty with or without associated stenting. Policy statements otherwise unchanged.
September 2019	Replace policy	Policy updated with review of literature through March 20, 2019; international guidelines removed, 2019 PMA information added; no references added. Policy statements unchanged except "investigational" changed to "not medically necessary" due to FDA PMA status.
September 2020	Replace policy	Policy updated with review of literature through March 13, 2020; references added. Policy statements unchanged.
September 2021	Replace policy	Policy updated with literature review through March 23, 2021; references added. Policy statements unchanged.
September 2022	Replace policy	Policy updated with literature review through March 14, 2022; references added. Minor editorial refinements to policy statements; intent unchanged.
September 2023	Replace policy	Policy updated with literature review through April 3, 2023; references added. Minor editorial refinements to policy statements; intent unchanged.

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.